Omnicell (OMCL) Misses Q3 EPS by 1c

October 27, 2016 5:39 PM EDT
Get Alerts OMCL Hot Sheet
Trade OMCL Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.40, $0.01 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $176.7 million versus the consensus estimate of $179.75 million.

"Omnicell completed another strong quarter marked by record revenues and market share gains," said Randall Lipps, Omnicell President, CEO and Chairman. "Omnicell's continued growth is the result of successfully broadening our product portfolio, expanding the markets we participate in, and partnering with our customers to address medication management across the full continuum of patient care. The Company is well positioned to take advantage of the great opportunities ahead," Mr. Lipps added.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Management Comments

Related Entities


Add Your Comment